“The development of new therapies and devices should reflect the dominant population that will ultimately use them—in the case of cardiovascular therapies and devices, this is exemplified by elderly patients”
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Research grants/contracts/trial, Steering Committee: Eli Lilly, Astra Zeneca, Pfizer
Consultantship: Cardiology Consultant, Bristol Myers Squibb; Women’s Advisory Board, CV Therapeutics; Sanofi-Aventis; NitroMed Heart Failure Advisory Board; Leadership Council for Improving Cardiovascular Care (LCIC) Executive Committee, Schering-Plough; GlaxoSmithKline; AstraZeneca AB; Abbott
Speakers Bureau (CME): Pfizer, Novartis, Merck, Bristol-Myers Squibb, Eli Lilly, NitroMed, CV Therapeutics